Timothy McAlindon to Wnt Signaling Pathway
This is a "connection" page, showing publications Timothy McAlindon has written about Wnt Signaling Pathway.
Connection Strength
0.307
-
McAlindon TE, Bannuru RR. Osteoarthritis in 2017: Latest advances in the management of knee OA. Nat Rev Rheumatol. 2018 02; 14(2):73-74.
Score: 0.135
-
Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, Skrepnik N, Armas E, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Hochberg MC. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 10; 25(10):1598-1606.
Score: 0.131
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 10; 72(10):1694-1706.
Score: 0.041